|1.||Solfrizzi, Vincenzo: 7 articles (10/2014 - 11/2010)|
|2.||Panza, Francesco: 7 articles (10/2014 - 11/2010)|
|3.||Imbimbo, Bruno P: 7 articles (10/2014 - 11/2010)|
|4.||Liu, Enchi: 6 articles (01/2016 - 04/2010)|
|5.||Grundman, Michael: 6 articles (08/2015 - 04/2010)|
|6.||Brashear, H Robert: 5 articles (01/2016 - 03/2012)|
|7.||Salloway, Stephen: 5 articles (08/2015 - 03/2012)|
|8.||Logroscino, Giancarlo: 5 articles (10/2014 - 12/2011)|
|9.||Seripa, Davide: 5 articles (09/2014 - 11/2010)|
|10.||Fox, Nick C: 4 articles (08/2015 - 04/2010)|
01/01/2011 - "These results suggest that, in this particular case, bapineuzumab immunotherapy neither resulted in detectable clearance of amyloid plaques nor prevented further cognitive impairment."
05/01/2013 - "The marginal effects observed in recent clinical studies of solanezumab, targeting monomeric Aβ, and bapineuzumab, targeting amyloid plaques, prompted expert comments that drug discovery efforts in Alzheimer's disease should focus on soluble forms of Aβ rather than fibrillar Aβ deposits found in amyloid plaques. "
|2.||Alzheimer Disease (Alzheimer's Disease)
02/01/2015 - "Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease."
03/01/2014 - "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of Aβ, were disappointing. "
01/23/2014 - "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease."
06/15/2010 - "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease."
04/01/2010 - "A single ascending dose study of bapineuzumab in patients with Alzheimer disease."
01/01/2011 - "Forty-eight days after the fourth bapineuzumab infusion was given, MRI revealed that the patient had developed lacunar infarcts and possible vasogenic edema, probably related to immunotherapy, but a subsequent MRI scan 38 days later demonstrated resolution of vasogenic edema. "
04/01/2010 - "The first passive immunotherapy trial with bapineuzumab, a humanized monoclonal antibody against the end terminus of Abeta, also encountered some dose dependent adverse events during the Phase II portion of the study, vasogenic edema in 12 cases, which were significantly over represented in ApoE4 carriers. "
12/15/2009 - "Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. "
01/01/2012 - "Indeed, several adverse events have been described like meningoencephalitis with AN1792, vasogenic edema and microhemorrhages with bapineuzumab. "
01/23/2014 - "The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. "
|5.||Cerebral Amyloid Angiopathy (Congophilic Angiopathy)
02/01/2012 - "Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no effects on incidence or severity of cerebral amyloid angiopathy-associated microhemorrhages, a severe side effect associated with bapineuzumab, another monoclonal antibody. "
|2.||Amyloid (Amyloid Fibrils)
|6.||Immunoglobulin G (IgG)
|8.||N- methyl- 2- (4'- methylaminophenyl)- 6- hydroxybenzothiazole
|9.||Apolipoproteins E (ApoE)
|10.||Biological Markers (Surrogate Marker)